The nurse is teaching a client about a new anti-dysrhythmic prescription. Which information should be included?

Anti-dysrhythmic medications are classified by their effect on the cardiac action potential. While they are intended to correct abnormal rhythms by altering ion channel conductance, they also have pro-arrhythmic potential, meaning they can paradoxically worsen existing arrhythmias or induce new, potentially lethal cardiac rhythms like Torsades de Pointes. A. Anti-dysrhythmic drugs are generally intended to decrease the cardiac workload by stabilizing the heart rate and rhythm. Increasing cardiac workload would be counterproductive, as it increases myocardial oxygen demand and can exacerbate heart failure or ischemia, which often coexist with rhythm disturbances in clinical settings. B. Most anti-dysrhythmic agents, particularly those in Classes II (beta-blockers) and IV (calcium channel blockers), are designed to slow the heart rate (bradycardia) rather than cause tachycardia. While some Class IA agents can have anticholinergic effects that mildly increase heart rate, tachycardia is not a universal or intended goal. C. The goal of anti-dysrhythmic therapy is typically to decrease, not increase, cardiac excitability. By prolonging the refractory period or slowing the rate of depolarization, these drugs make the heart tissue less sensitive to the abnormal electrical triggers that cause tachyarrhythmias and re-entry circuits within the myocardium. D. All anti-dysrhythmic medications have the potential to be PRO-ARRHYTHMIC. By altering the electrical properties of the heart, they CAN INCREASE THE INCIDENCE of new or different DYSRHYTHMIAS. This is a critical safety point; patients must be monitored closely for EKG changes, such as QT prolongation, that signify increased risk.